Top

International Journal of Clinical Pharmacy

Published in:

01-08-2021 | Stroke | Research Article

Stroke patients’ support: evaluation of knowledge, practices and training needs of French community pharmacists

Authors: Sophie Khettar, Marie Viprey, Julie Haesebaert, Sophie Jacquin-Courtois, Jacques Luauté, Laura Mechtouff, Laurent Derex, Gilles Rode, Claude Dussart, Audrey Janoly-Dumenil

Published in: International Journal of Clinical Pharmacy | Issue 4/2021

Abstract

Background Stroke represents a major Public Health issue in industrialized countries because of its frequency and severity. In secondary stroke prevention, treatment efficacy is correlated to medication adherence. However, it remains suboptimal in stroke patients. Community pharmacists, in light of their positioning in the care pathway and proximity to patients, can play an essential role in patient support and improving treatment adherence. However, it is currently unknown whether pharmacists are ready to perform this task. Objective Evaluate knowledge, practices and training needs for community pharmacists in therapeutic stroke management to improve long term care for stroke patients. Setting Community pharmacies in the Rhone Alpes region (France). Method We conducted a cross sectional study via a standardized self-assessment questionnaire consisting of 40 questions divided into three parts. The latter was designed by a multidisciplinary team and distributed electronically to community pharmacists of the Rhône-Alpes region (France). Main outcome measure (a) global knowledge score on the pathology, risk factors and clinical care management, (b) description of the support practices for stroke patients, (c) training needs for pharmacists. Results The 104 participants presented a moderate level of knowledge (global score: 12/20 ± 3). Topics best mastered were: pathophysiology, target blood pressure and place of antiplatelets in the therapeutic strategy. Knowledge items that needed improvement were: warning signs correctly identified by 44% of participants, time delay for thrombolysis for which 14% answered correctly, target glycated hemoglobin levels were correct for 41%, and the 3 recommended antihypertensive drug classes were only identified by 5% of participants. Patient education received from pharmacists concerned dosage (89%), treatment adherence (88%), benefits (66%) and administration modalities of medicines (64%), management of risk factors (75% for diet, 73% for physical activity, 70% for smoking and 53% for alcohol). All pharmacists wanted additional training on risk factors and clinical management guidelines. Conclusion Based on this small study, the fragmented knowledge and varied practices promote the need for further training for pharmacists to optimize support of stroke patients. This study promotes the elaboration of training systems adapted to pharmacists’ needs. This will help support the development of a targeted pharmaceutical care approach for stroke patients.

Available only for authorised users

Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. Bull World Health Organ. 2016;94:634.CrossRef

HAS-Recommandations de bonnes pratiques. Prévention vasculaire après un infarctus cérébral ou un accident ischémique transitoire—Actualisation—Juillet 2014 [HAS-Best practices updates. Vascular prevention after a stroke or transient ischemic attack—Updated-July 2014]. [Update June 2018]. https://www.has-sante.fr/portail/upload/docs/application/pdf/2014-09/avc_argumentaire.pdf. Accessed 3 July 2018.

HAS-Guide Affection Longue Durée. Accident vasculaire cérébral-Mars 2007 [HAS-Long term care guide-Stroke-March 2007]. http://www.has-sante.fr/portail/upload/docs/application/pdf/07-042_traceur_guide-adl-avc.pdf. Accessed 2 August 2016.

HAS-Recommandations de bonnes pratiques. Accident vasculaire cérébral: prise en charge précoce (alerte, phase préhospitalière, phase hospitalière initiale, indications de la thrombolyse)-Argumentaire-Mai 2009. [HAS-Best practices guidelines. Stroke: early care management (alert, prehospitalization phase, initial hospitalization phase, indications for thrombolysis)-Arguments-May 2009. http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-07/avc_prise_en_charge_precoce_-_argumentaire.pdf. Accessed 2 August 2016.

Glader EL, Sjolander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41:397–401. https://doi.org/10.1161/STROKEAHA.109.566950.CrossRefPubMed

Bushnell CD, Zimmer LO, Pan W, Olson DM, Zhao X, Meteleva T, Schwamm L, Ovbiagele B, Williams L, Labresh KA, Peterson ED. Adherence Evaluation After Ischemic Stroke-Longitudinal Investigators, Persistence with stroke prevention medications 3 months after hospitalization. Arch Neurol. 2010;67(12):1456–63. https://doi.org/10.1001/archneurol.2010.190.CrossRefPubMed

Perreault S, Yu AYX, Côté R, Dragomir B, White-Guay B, Dumas S. Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes. Neurology. 2012;79:2037–43. https://doi.org/10.1212/WNL.0b013e3182749e56.CrossRefPubMedPubMedCentral

Burke JP, Sander S, Shah H, Zarotsky V, Henk H. Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. Curr Med Res Opin. 2010;26:1023–30. https://doi.org/10.1185/03007991003670563.CrossRefPubMed

Hohmann C, Klotz JM, Radziwill R, Jacobs AH, Kissel T. Pharmaceutical care for patients with ischemic stroke: improving the patients quality of life. Pharm World Sci. 2009;31:550–8. https://doi.org/10.1007/s11096-009-9315-y.CrossRefPubMed

10.

O’Carroll RE, Chambers JA, Dennis M, Sudlow C, Johnston M. Improving adherence to medication in stroke survivors: a pilot randomised controlled trial. Ann Behav Med. 2013;46:358–68. https://doi.org/10.1007/s12160-013-9515-5.CrossRefPubMed

11.

Sit JW, Yip VY, Ko SK, Gun AP, Lee JS. A quasi-experimental study on a community-based stroke prevention programme for clients with minor stroke. J Clin Nurs. 2007;16:272–81. https://doi.org/10.1111/j.1365-2702.2005.01522.x.CrossRefPubMed

12.

Ovbiagele B, Saver JL, Fredieu A, Suzuki A, McNair N, Dandekar A, et al. PROTECT: a coordinated stroke treatment program to prevent recurrent thromboembolic events. Neurology. 2004;63:1217–22. https://doi.org/10.1212/01.wnl.0000140493.83607.f1.CrossRefPubMed

13.

Arif H, Aijaz B, Islam M, Aftab U, Kumar S, Shafqat S. Drug compliance after stroke and myocardial infarction: a comparative study. Neurol India. 2007;55(2):130–5.CrossRef

14.

Bushnell C, Olson D, Zhao X, Pan W, Zimmer L, Goldstein L, et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology. 2011;77(12):1182–90.CrossRef

15.

Chambers JA, O’Carroll RE, Hamilton B, Whittaker J, Johnston M, Sudlow C, Dennis M. Adherence to medication in stroke survivors: a qualitative comparison of low and high adherers. Br J Health Psychol. 2011;16(3):592–609.CrossRef

16.

Sjölander M, Eriksson M, Glader EL. The association between patients’ beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire survey. BMJ Open. 2013;3(9):e003551.CrossRef

17.

Souter C, Kinnear A, Kinnear M, Mead G. Optimisation of secondary prevention of stroke: a qualitative study of stroke patients’ beliefs, concerns and difficulties with their medicines. Int J Pharm Pract. 2014;22(6):424–32.CrossRef

18.

Bauler S, Jacquin-Courtois S, Haesebaert J, Luaute J, Coudeyre E, Feutrier C, Allenet B, Decullier E, Rode G, Janoly-Dumenil A. Barriers and facilitators for medication adherence in stroke patients: a qualitative study conducted in French neurological rehabilitation units. Eur Neurol. 2014;72(5–6):262–70.CrossRef

19.

Milosavljevic A, Aspden T, Harrison J. Community pharmacist-led interventions and their impact on patients’ medication adherence and other health outcomes: a systematic review. Int J Pharm Pract. 2018;26(5):387–97. https://doi.org/10.1111/ijpp.12462.CrossRefPubMed

20.

McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, et al. SCRIP-HTN Investigators. A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN). Arch Intern Med. 2008;168:2355–61. https://doi.org/10.1001/archinte.168.21.2355.CrossRefPubMed

21.

Tsuyuki RT, Al Hamarneh YN, Jones CA, Hemmelgarn BR. The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH trial. J Am Coll Cardiol. 2016;67:2846–54. https://doi.org/10.1016/j.jacc.2016.03.528.CrossRefPubMed

22.

Amariles P, Sabater-Hernández D, García-Jiménez E, Rodríguez-Chamorro MA, Prats-Más R, Marín-Magán F, et al. Effectiveness of Dader Method for pharmaceutical care on control of blood pressure and total cholesterol in outpatients with cardiovascular disease or cardiovascular risk: EMDADER-CV randomized controlled trial. J Manag Care Pharm. 2012;18:311–23. https://doi.org/10.18553/jmcp.2012.18.4.311.CrossRefPubMed

23.

Cheema E, Sutcliffe P, Singer DR. The impact of interventions by pharmacists in community pharmacies on control of hypertension: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2014;78:1238–47. https://doi.org/10.1111/bcp.12452.CrossRefPubMedPubMedCentral

24.

Houle SK, Chuck AW, McAlister FA, Tsuyuki RT. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN). Pharmacotherapy. 2012;32:527–37. https://doi.org/10.1002/j.1875-9114.2012.01097.x.CrossRefPubMed

25.

Casset A, Meunier-Spitz M, Rebotier P, Lefèvre H, Barth C, Heitz C, et al. Asthma management and inhalation techniques among community pharmacists in 2009: a comparison with the 1999 survey. J Asthma. 2014;51:964–73. https://doi.org/10.3109/02770903.2014.936446.CrossRefPubMed

26.

Armstrong EP, Campbell C, Van Allen A, Vincent E. Skin cancer knowledge and prevention counseling among Arizona pharmacists. J Pharm Pract. 2010;23:358–66. https://doi.org/10.1177/0897190010366934.CrossRefPubMed

27.

Saengcharoen W, Lerkiatbundit S. Migraine management in community pharmacies: practice patterns and knowledge of pharmacy personnel in Thailand. Headache. 2013;53:1451–63. https://doi.org/10.1111/head.12163.CrossRefPubMed

28.

Khanna R, Jariwala K. Awareness and knowledge of autism among pharmacists. Res Social Adm Pharm. 2012;8:464–71. https://doi.org/10.1016/j.sapharm.2011.11.002.CrossRefPubMed

29.

Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014;111:1167–76. https://doi.org/10.1160/TH14-03-0231.CrossRefPubMed

30.

Puspitasari HP, Aslani P, Krass I. Australian community pharmacists’ awareness and practice in supporting secondary prevention of cardiovascular disease. Int J Clin Pharm. 2013;35:1218–28. https://doi.org/10.1007/s11096-013-9854-0.CrossRefPubMed

31.

Papastergiou J, Kheir N, Ladova K, Rydant S, De Rango F, Antoniou S, et al. Pharmacists’ confidence when providing pharmaceutical care on anticoagulants, a multinational survey. Int J Clin Pharm. 2017;39:1282–90. https://doi.org/10.1007/s11096-017-0551-2.CrossRefPubMedPubMedCentral

32.

Denetclaw TH, Cefalu P, Manila LL, Panagotacos JJ. Needs analysis for educating community pharmacists to interface with prehospital stroke chain of survival. J Stroke Cerebrovasc Dis. 2014;23:209–12. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.11.017.CrossRefPubMed

33.

Monseau AJ, Whiteman C, Crocco TJ, Davis SM, Barkley J. Advice on stroke provided by pharmacies in the United States: implications for treatment and care. South Med J. 2015;108:219–22. https://doi.org/10.14423/SMJ.0000000000000262.CrossRefPubMed

34.

Grimes T, Duggan C, Gallagher P, Strawbridge J. Care of the stroke patient-communication between the community pharmacist and prescribers in the Republic of Ireland. Pharm World Sci. 2009;31:648–55. https://doi.org/10.1007/s11096-009-9322-z.CrossRefPubMed

35.

Royal College of Physicians. National clinical guideline for stroke. London: RCP; 2012. http://www.rcplondon.ac.uk/sites/default/files/nationalclinical-guidelines-for-stroke-fourth-edition.pdf. Accessed 2 Aug 2016.

36.

Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.

37.

Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, Hennerici M, Simunovic L, Zivin JA, Welch KM, on behalf of the SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2007;38:3198–204.CrossRef

38.

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.CrossRef

39.

Ordre National des Pharmaciens, Démographie 2015-brochure nationale [National Order of Pharmacists, Demographics 2015-National brochure]. http://www.ordre.pharmacien.fr/Communications/Elements-demographiques/Les-pharmaciens-Panorama-au-1er-janvier-2015. Accessed 2 Aug 2016.

40.

Ministère de la santé et des sports. Ministère de la santé et des sports-Plan d’actions national « accidents vasculaires cérébraux 2010-2014 »-Avril 2010 [Ministry of Health and Sports-National action plan « Stroke 2010–2014 »-April 2010]. http://www.sante.gouv.fr/IMG/pdf/plan_actions_AVC_-_17avr2010.pdf. Accessed 23 April 2015.

41.

Derex L, Adeleine P, Nighoghossian N, Honnorat J, Trouillas P. Factors influencing early admission in a French stroke unit. Stroke. 2002;33:153–9.CrossRef

42.

Ayerbe L, Ayis S, Crichton S, Wolfe CD, Rudd AG. The natural history of depression up to 15 years after stroke: the South London Stroke Register. Stroke. 2013;44:1105–10. https://doi.org/10.1161/STROKEAHA.111.679340.CrossRefPubMed

43.

O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. INTERSTROKE investigators. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–23. https://doi.org/10.1016/S0140-6736(10)60834-3.CrossRefPubMed

44.

Kushner FG, Hand M, Smith SC, King SB, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2009;54:2205–41. https://doi.org/10.1016/j.jacc.2009.10.015.CrossRefPubMed

45.

AFSSAPS-Communiqué de presse-L’Afssaps rappelle les conditions d’utilisation et les précautions d’emploi des nouveaux anticoagulants oraux (dabigatran et rivaroxaban) dans la fibrillation auriculaire-27 Juillet 2012. [The Afssaps recalls the conditions of use and the precautions for the use of new oral anticoagulants (dabigatran and rivaroxaban) in atrial fibrillation]. https://www.ansm.sante.fr/S-informer/Communiques-Communiques-Points-presse/L-Afssaps-rappelle-les-conditions-d-utilisation-et-les-precautions-d-emploi-des-nouveaux-anticoagulants-oraux-dabigatran-et-rivaroxaban-dans-la-fibrillation-auriculaire-Communique. Accessed 3 Nov 2020.

46.

HAS-Fibrillation auriculaire non valvulaire-Quelle place pour les anticoagulants oraux non antivitamine K: apixaban (Eliquis^®), dabigatran (Pradaxa^®) et rivaroxaban (Xarelto^®)–Juillet 2013. Non-valvular atrial fibrillation—What place for non-vitamin K oral anticoagulants: apixaban (Eliquis^®), dabigatran (Pradaxa^®) and rivaroxaban (Xarelto^®)]. https://www.has-sante.fr/upload/docs/application/pdf/2013-07/fs_bum_naco_v5.pdf. Accessed 3 Nov 2020.

47.

Puspitasari HP, Aslani P, Krass I. A review of counseling practices on prescription medicines in community pharmacies. Res Soc Adm Pharm. 2009;5:197–210. https://doi.org/10.1016/j.sapharm.2008.08.006.CrossRef

48.

Puspitasari HP, Aslani P, Krass I. Pharmacists’ and consumers’ viewpoints on counselling on prescription medicines in Australian community pharmacies. Int J Pharm Pract. 2010;18:202–8. https://doi.org/10.1111/j.2042-7174.2010.00041.x.CrossRefPubMed

49.

Colloca L, Finniss D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA. 2012;307:567–8. https://doi.org/10.1001/jama.2012.115.CrossRefPubMedPubMedCentral

50.

Tan K, Petrie KJ, Faasse K, Bolland MJ, Grey A. Unhelpful information about adverse drug reactions. BMJ. 2014;349:g5019. https://doi.org/10.1136/bmj.g5019.CrossRefPubMed

51.

de Macquart TD, Hejblum G, Fernandez C, Cohen A, Antignac M. Discrepancies between patients’ preferences and educational programs on oral anticoagulant therapy: a survey in community pharmacies and hospital consultations. PLoS One. 2016;11(1):e0146927. https://doi.org/10.1371/journal.pone.0146927.CrossRef

52.

Crayton E, Fahey M, Ashworth M, Besser SJ, Weinman J, Wright AJ. Psychological determinants of medication adherence in stroke survivors: a systematic review of observational studies. Ann Behav Med. 2017;51(6):833–45. https://doi.org/10.1007/s12160-017-9906-0.CrossRefPubMed

53.

Smith LN, Craig LE, Weir CJ, McAlpine CH. Stroke education for healthcare professionals: making it fit for purpose. Nurse Educ Today. 2008;28:337–47. https://doi.org/10.1016/j.nedt.2007.06.008.CrossRefPubMed

Title: Stroke patients’ support: evaluation of knowledge, practices and training needs of French community pharmacists
Authors: Sophie Khettar
Marie Viprey
Julie Haesebaert
Sophie Jacquin-Courtois
Jacques Luauté
Laura Mechtouff
Laurent Derex
Gilles Rode
Claude Dussart
Audrey Janoly-Dumenil
Publication date: 01-08-2021
Publisher: Springer International Publishing
Keyword: Stroke
Published in: International Journal of Clinical Pharmacy / Issue 4/2021
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-020-01204-z

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Stroke patients’ support: evaluation of knowledge, practices and training needs of French community pharmacists

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Perspectives of community pharmacists in Pakistan about practice change and implementation of extended pharmacy services: a mixed method study

Therapeutic optimization through goal-oriented prescription in nursing homes

Spontaneous reports of adverse drug reactions related to oral anticoagulants in the Czech Republic

Answers to the authors of the “Letter to the Editor”: A comparative study between non colistin based combinations for treatment of infections caused by extensive drug resistant Acinetobacter baumannii: comments

Development of innovative simulation teaching for advanced general practice clinical pharmacists

The integral role of the clinical pharmacist in drug-assisted intubation at a newly established children’s major trauma center

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page